PARKINSON'S DISEASE
LATE-ONSET

brain-synapcell

PARKINSON'D disease.
AT THE BRAIN LEVEL.

Inside the brain, neurons in the pars compacta of the substantia nigra normally transmit dopamine to the striatum. In Parkinson’s disease (PD), the degeneration of dopaminergic neurons leads to dysfunction of this neuronal circuit, especially in the motor cortical areas. As a result, PD patients have their life severely impacted by motor disabilities or abnormalities.

PRECLINICAL RESEARCH

needs predictive translational objective functional biomarkers

BETA WAVES
TRANSLATIONAL EEG biomarker

Using EEG recording, a closer look at the brain’s neural activity reveals excessive synchronization in the Beta frequency range of PD patients’ motor cortex.

These low frequencies (Beta waves) are transiently reduced by dopamine agonists such as L-DOPA. Likewise, the 6-OHDA rat model of Parkinson’s disease shows a stable and pharmacosensitive Beta signature in vivo, which makes it clinically-relevant for preclinical anti-PD compound testing.

Augment the predictability of your compound performance on PD syndrome with the 6-OHDA model and BetaPark!

GAMMAPARK-drug-discovery-on-cns-disorders-synapcell
GAMMAPARK-drug-discovery-on-cns-disorders-synapcell

BETApark is objective & stable over time

A stable and specific Beta oscillation (BetaPark) is found in the motor cortex of the unilateral 6-OHDA rat model of PD, as found in PD patients.

This translational biomarker is:

  • Pharmacosensitive
  • Incredibly stable over time
  • Objective, measured inside the motor cortex
  • Exclusively revealed by Cue® and EEG
Challenge BetaPark with your own compound in vivo and see how it compares to standards of care.

PHARMACOSENSITIVE biomarker of parkinson's disease

Modulated by a pharmacology of reference (Dopamine agonists), BetaPark is a pharmacosensitive biomarker, 

BetaPark is expressed in the 6-OHDA rat model and is stable over time.

We quantify the pharmacodynamic effects of your compound in vivo, on BetaPark and objectively evaluate how it compares to reference drugs in acute or chronic paradigms.

BETAPARK-DOPAMINE-AGONIST-SynapCell

DOPAMINERGIC DRUGS transiently stop betapark

BETAPARK-acute-ldopa-6-and-20-SynapCell

Time course of the effect of L-Dopa at 6 and 20mg/kg i.p. on the pathological BetaPark oscillation (25-45Hz) in the motor cortex of 6-OHDA rats with treatment time.

Error bars represent +/- sem (n=7 rats). Stats: RM two-way ANOVA with Sidak’s post-hoc test versus vehicle.

Let's talk about your next project